Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyCommunity Care IPA Optune Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedCommunity Care Independent Practice AssociationPolicy CP.MP.145

    Clinical Policy: Electric Tumor Treating Fields (Optune)

    Customize your policy alerts

    Sign up for communitycareindependentpracticeassociation Policy CP.MP.145 alerts

    Get alerted when Policy CP.MP.145 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity and prior-authorization coverage for Optune electric tumor treating fields in adults with newly diagnosed or recurrent glioblastoma. It also addresses continuation therapy, contraindications, unsupported indications, NovoTal planning software, and related billing codes.

    Policy Summary
    PayerCommunity Care Independent Practice Association
    PolicyClinical Policy: Electric Tumor Treating Fields (Optune)
    Policy CodePolicy CP.MP.145
    Change TypeModified
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization for an initial 90-day course and document that all clinical requirements are met, contraindications are absent, and device use will be 18 hours per day.
    SourceLink
    POLICY UPDATE CHANGES

    The October 2026 revision requires chemoradiation, rather than radiation alone, to be completed before Optune is used with temozolomide for newly diagnosed glioblastoma.

    The October 2026 revision added a requirement that newly diagnosed glioblastoma show no evidence of progression by RANO criteria.

    The policy added an age restriction requiring adults older than 22 years for medically necessary TTF therapy.

    The policy added an 18-hours-per-day device-wear requirement for initial therapy and continuation therapy, including prior-period compliance for continuation.

    The performance-status threshold was revised from a Karnofsky Performance Status of at least 70 to at least 60.

    >22Minimum age for medically necessary TTF therapy

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    18 h/day
    Required device wear duration
    90 daysInitial and continuation authorization intervals
    KPS ≥60Required performance status
    2Covered clinical settings
    2Referenced billing codes

    Medical Necessity and Exclusions

    Initial therapy

    Covered as medically necessary for adults older than 22 years when all applicable criteria are met.

    Initial 90-day TTF therapy

    • Covered indication

      • Newly diagnosed glioblastoma

        • Newly diagnosed requirements: The glioblastoma is in the supratentorial region; the member/enrollee has a Karnofsky Performance Status of at least 60; TTF will be delivered in conjunction with temozolomide after standard surgical and chemoradiation therapies have been completed; and there is no evidence of progression by RANO criteria.KPS ≥60; no progression by RANO
      • Recurrent glioblastoma

        • Recurrent requirements: The glioblastoma is in the supratentorial region; the member/enrollee has a Karnofsky Performance Status of at least 60; and TTF will be used as monotherapy after standard treatment with chemotherapy, surgery, and/or radiation.KPS ≥60
    • No contraindications: None of the listed contraindications is present.

      Contraindications include specified implanted medical devices, a skull defect such as missing bone without replacement or a bullet fragment, pregnancy, and known sensitivity to conductive hydrogels.

    • Adherence agreement: The member/enrollee agrees to wear the TTF device for 18 hours per day.18 hours/day

    Continuation therapy

    Covered for an additional 90 days when both continuation requirements are met.

    • No progression: There has been no disease progression in the last 90 days of TTF therapy.No progression during prior 90 days
    • Ongoing adherence: The member/enrollee agrees to wear the TTF device for 18 hours per day and was compliant with that requirement during the prior authorization period.18 hours/day

    Other indications

    The policy does not establish sufficient evidence to support TTF therapy for indications outside the covered glioblastoma pathways.

    Other indications: TTF therapy for indications outside the specified newly diagnosed or recurrent glioblastoma pathways is not supported by sufficient evidence under this policy.

    NovoTal

    The policy does not establish sufficient evidence for NovoTal computer mapping software.

    NovoTal planning software: There is insufficient evidence to establish the efficacy of NovoTal for planning TTF therapy.

    NovoTal is a computer software-planning tool used to help direct placement of transducer arrays for TTF therapy.

    Coverage is excluded when the member has an implanted medical device, including a deep brain stimulator, spinal cord stimulator, vagus nerve stimulator, pacemaker, defibrillator, or programmable shunt.

    Coverage is excluded for a skull defect, such as missing bone without replacement, or for a retained bullet fragment.

    Pregnancy is a contraindication to TTF therapy under this policy.

    Coverage is excluded for known sensitivity to conductive hydrogels, including gels used with electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes.

    TTF therapy for indications other than the covered newly diagnosed or recurrent glioblastoma pathways is not supported by sufficient evidence under this policy.

    The efficacy of NovoTal computer mapping software for planning TTF therapy has not been established by sufficient evidence. NovoTal is a software-planning tool intended to help direct placement of transducer arrays.

    Coding and Coverage Parameters

    Referenced HCPCS CodesHCPCS
    A4555Electrode/transducer for use with electrical stimulation device used for cancer treatment, replacement only.
    Referenced HCPCS CodesHCPCS
    E0766Electrical stimulation device used for cancer treatment, includes all accessories, any type.
    Age
    Minimum ageAdults older than 22 years
    Coverage applicationApplies to medically necessary tumor treating fields therapy when the applicable criteria are met
    Age-related denial riskRequests may be denied for patients aged 22 years or younger
    Karnofsky Performance Status
    Required scoreKarnofsky Performance Status of at least 60
    Newly diagnosed diseaseRequired for newly diagnosed supratentorial glioblastoma
    Recurrent disease

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Initial 90-Day Authorization

    Obtain authorization for the initial 90-day course of tumor treating fields (TTF) therapy before treatment. Coverage applies to adults older than 22 years who meet a covered glioblastoma indication, have no listed contraindication, and agree to wear the device for 18 hours per day.

    • Request is for an initial 90 days of TTF therapy.
    • Member/enrollee is older than 22 years.
    • Covered indication is either newly diagnosed or recurrent glioblastoma meeting the applicable clinical criteria.
    • Member/enrollee agrees to wear the TTF device 18 hours per day.
    Prior Authorization

    Additional 90-Day Authorization

    Obtain a new authorization for each additional 90-day period. Continuation requires no disease progression during the preceding 90 days, documented compliance with the device, and an ongoing agreement to wear it for 18 hours per day.

    • Request is for an additional 90 days of therapy.

    Therapy Overview

    Tumor treating fields (TTF) are low-intensity alternating electrical fields delivered to the brain through transducer arrays placed on the scalp. The fields are intended to disrupt mitosis and cause cancer-cell death while having limited effects on nondividing cells. Optune is used as an adjunct to standard treatment for newly diagnosed glioblastoma and as monotherapy after standard treatment for recurrent glioblastoma.

    Key Terms

    Tumor Treating Fields (TTF)
    Therapy typeAlternating electric field therapy, also known as tumor treating fields
    Delivery methodApplied to the brain through electrodes placed on the scalp
    Therapeutic fieldCreates a low-intensity alternating electric field within the tumor
    Optune Gio
    Device typePortable medical device that generates low-intensity tumor treating fields
    Device placementWorn throughout the day and attached to the head by electrodes
    Manufacturer

    Therapy Setting

    First-line therapy

    For first-line therapy, coverage follows the newly diagnosed glioblastoma pathway.

    First-line therapy: TTF is delivered with temozolomide after standard surgical and chemoradiation therapies are completed, and there is no evidence of progression by RANO criteria.KPS ≥60; no progression by RANO

    Salvage therapy

    For salvage therapy, coverage follows the recurrent glioblastoma pathway.

    Salvage therapy: TTF is used as monotherapy after standard treatment with chemotherapy, surgery, and/or radiation.KPS ≥60

    Biomarker Status

    MGMT Promoter Status
    Possible statusMethylated
    Possible statusUnmethylated or indeterminate
    Coverage requirementThe policy does not require a specific MGMT promoter status

    Covered Treatment Pathways

    RegimenClinical criteriaCoverage
    Optune TTF with temozolomideNewly diagnosed, histologically confirmed supratentorial glioblastoma after standard surgery and chemoradiation; Karnofsky Performance Status ≥60; no progression by RANO criteria.Covered
    RegimenClinical criteriaCoverage
    Optune TTF monotherapyRecurrent, histologically or radiologically confirmed supratentorial glioblastoma after standard chemotherapy, surgery, and/or radiation; Karnofsky Performance Status ≥60.Covered
    RegimenClinical settingCoverage
    TTF therapy outside the specified glioblastoma criteriaIndications other than newly diagnosed or recurrent supratentorial glioblastoma meeting the policy criteria.Not covered
    Policy Summary
    PayerCommunity Care Independent Practice Association
    PolicyClinical Policy: Electric Tumor Treating Fields (Optune)
    Policy CodePolicy CP.MP.145
    Change TypeModified
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization for an initial 90-day course and document that all clinical requirements are met, contraindications are absent, and device use will be 18 hours per day.
    SourceLink
    On This Page
    Medical Necessity and ExclusionsCoding and Coverage ParametersAuthorization, Documentation, and Denial RisksTherapy OverviewKey TermsTherapy SettingBiomarker StatusCovered Treatment Pathways
    Required for recurrent supratentorial glioblastoma
    Device Wear Duration
    Daily wear requirement18 hours per day
    Initial therapyThe member must agree to wear the device for 18 hours per day during the initial authorization period
    Continuation therapyThe member must agree to continue 18-hours-per-day wear and must have complied during the prior authorization period
    Authorization Duration
    Initial authorization90 days of tumor treating fields therapy
    Continuation authorizationAn additional 90 days of therapy
    Continuation conditionAdditional authorization requires no disease progression during the preceding 90 days
  1. No disease progression occurred during the last 90 days of TTF therapy.
  2. Member/enrollee was compliant with the 18-hours-per-day requirement during the prior authorization period.
  3. Member/enrollee agrees to continue wearing the device 18 hours per day.
  4. Billing Rule

    Review Medicare and Medicaid Coverage Requirements

    Before applying this policy's criteria, review all applicable Medicare coverage requirements. For Medicaid members/enrollees, state Medicaid provisions control when they conflict with this policy.

    • Review applicable Medicare National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Medicare Coverage Articles.
    • For Medicare information, refer to the CMS website.
    • For Medicaid, consult the applicable state Medicaid manual; conflicting state coverage provisions take precedence.
    Documentation Required

    Initial Clinical Documentation

    Include sufficient clinical documentation with an initial request to establish the member/enrollee's age, diagnosis, disease location, performance status, treatment sequence, disease status, and planned use of TTF therapy.

    • Document age older than 22 years.
    • For newly diagnosed disease, provide histologic confirmation of glioblastoma, supratentorial location, Karnofsky Performance Status (KPS) of at least 60, completion of standard surgery and chemoradiation, planned concurrent temozolomide, and no progression by Response Assessment in Neuro-Oncology (RANO) criteria.
    • For recurrent disease, provide histologic or radiologic confirmation, supratentorial location, KPS of at least 60, and documentation that TTF will be used as monotherapy after standard chemotherapy, surgery, and/or radiation.
    • Document the planned TTF regimen and the member/enrollee's agreement to wear the device 18 hours per day.
    Documentation Required

    Continuation Documentation

    For continuation requests, document the preceding authorization period and demonstrate that the member/enrollee remains eligible for therapy.

    • Document that there was no disease progression during the preceding 90 days of TTF therapy.
    • Provide device-use or compliance documentation showing adherence to 18 hours per day during the prior authorization period.
    • Document the member/enrollee's agreement to continue wearing the device 18 hours per day.
    Documentation Required

    Contraindication Screening

    Screen for contraindications before submitting an initial request and document the results. TTF therapy should not be authorized when an excluded implanted device, qualifying skull defect, pregnancy, or known conductive-hydrogel sensitivity is present.

    • Check for implanted medical devices, including deep brain or spinal cord stimulators, vagus nerve stimulators, pacemakers, defibrillators, and programmable shunts.
    • Assess for a skull defect, including missing bone without replacement or a bullet fragment.
    • Assess pregnancy status.
    • Assess known sensitivity to conductive hydrogels, such as gels used with ECG stickers or TENS electrodes.
    Denial Risk

    Initial Eligibility Failure

    An initial request is at risk of denial when the member/enrollee is 22 years old or younger, the disease does not meet a covered glioblastoma indication, or required clinical criteria are not met.

    • Age does not exceed 22 years.
    • Newly diagnosed glioblastoma is not histologically confirmed, is not supratentorial, KPS is below 60, standard surgical and chemoradiation therapies are incomplete, temozolomide is not planned as required, or progression is present by RANO criteria.
    • Recurrent glioblastoma is not histologically or radiologically confirmed, is not supratentorial, KPS is below 60, or TTF is not planned as monotherapy after standard chemotherapy, surgery, and/or radiation.
    Denial Risk

    Contraindications

    Do not proceed with an initial request when a listed contraindication is present, including an excluded implanted device, qualifying skull defect, pregnancy, or known sensitivity to conductive hydrogels.

    • Excluded implanted device: deep brain stimulator, spinal cord stimulator, vagus nerve stimulator, pacemaker, defibrillator, or programmable shunt.
    • Skull defect with missing bone and no replacement, or a bullet fragment.
    • Pregnancy.
    • Known sensitivity to conductive hydrogels used with ECG stickers or TENS electrodes.
    Denial Risk

    Continuation Failure

    An additional 90-day request is at risk of denial when the member/enrollee progressed during the preceding authorization period or did not comply with the required device use.

    • Disease progression occurred during the last 90 days of TTF therapy.
    • The member/enrollee was not compliant with wearing the device 18 hours per day during the prior authorization period.
    • The member/enrollee does not agree to continue wearing the device 18 hours per day.
    Denial Risk

    Other Indications

    TTF therapy is not supported under this policy for indications other than the covered newly diagnosed or recurrent glioblastoma criteria. Requests for other indications are at risk of denial because evidence is insufficient.

    • Do not assume coverage for an indication outside the specified glioblastoma criteria.
    • Review applicable Medicare and state Medicaid requirements when those programs apply.
    Denial Risk

    NovoTal Planning Software

    The policy finds insufficient evidence to establish the efficacy of NovoTal computer mapping software for planning TTF therapy. Requests relying on NovoTal should not be represented as supported solely because the software was used.

    • NovoTal is a computer software-planning tool used to direct placement of transducer arrays.
    • Evidence identified in the policy is limited to a case series, physician-use study, and two review articles; several authors reported ties to Novocure.
    • TTF coverage criteria do not establish NovoTal as an efficacious or required planning technology.
    NovoCure
    RANO Criteria
    Full nameResponse Assessment in Neuro-Oncology criteria
    Clinical useUsed to assess disease progression in glioblastoma
    Coverage applicationNewly diagnosed glioblastoma must show no evidence of progression by these criteria
    NovoTal
    Tool typeComputer software-planning tool
    PurposeHelps direct placement of transducer arrays for tumor treating fields therapy
    Evidence statusThe policy finds insufficient evidence to establish its efficacy for planning tumor treating fields therapy